We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Rua Life Sciences Plc | LSE:RUA | London | Ordinary Share | GB0033360586 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 11.50 | 0.00 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 11.00 | 12.00 | 11.50 | 11.50 | 11.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Plastics,resins,elastomers | 2.19M | -1.44M | -0.0232 | -4.96 | 7.14M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:17:28 | O | 140,000 | 11.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 06/5/2025 | 09:30 | UK RNS | RUA Life Sciences PLC Director/PDMR Shareholding |
| 30/4/2025 | 11:45 | UK RNS | RUA Life Sciences PLC Change of Registered Office |
| 24/4/2025 | 08:14 | ALNC |  *RUA Life Sciences expects FY25 GBP4.1m revenue growth, up from GBP2.2m in.. |
| 24/4/2025 | 07:00 | UK RNS | RUA Life Sciences PLC Trading Update |
| 04/2/2025 | 07:00 | UK RNS | RUA Life Sciences PLC Director/PDMR Shareholding |
| 03/2/2025 | 14:26 | ALNC | RUA Life shares rise as newly bought ABISS turns profit in 2024 |
| 03/2/2025 | 07:00 | UK RNS | RUA Life Sciences PLC Acquisition Update |
| 29/1/2025 | 07:00 | UK RNS | RUA Life Sciences PLC New Supply Agreement |
| 11/12/2024 | 12:39 | ALNC | RUA Life Sciences swings to pretax profit in its first half |
| 11/12/2024 | 07:00 | UK RNS | RUA Life Sciences PLC Interim Results |
Rua Life Sciences (RUA) Share Charts1 Year Rua Life Sciences Chart |
|
1 Month Rua Life Sciences Chart |
Intraday Rua Life Sciences Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 08/5/2025 | 10:09 | RUA Life Sciences - Elast-Eon Enabled MedTech | 3,880 |
| 06/4/2024 | 09:54 | purple the twat is a nasty TROLL | 24 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-05-23 10:10:29 | 11.50 | 140,000 | 16,100.00 | O |
| 2025-05-23 10:10:25 | 11.50 | 140,000 | 16,100.00 | O |
| Top Posts |
|---|
Posted at 24/5/2025 09:20 by Rua Life Sciences Daily Update Rua Life Sciences Plc is listed in the Plastics,resins,elastomers sector of the London Stock Exchange with ticker RUA. The last closing price for Rua Life Sciences was 11.50p.Rua Life Sciences currently has 62,060,272 shares in issue. The market capitalisation of Rua Life Sciences is £7,136,931. Rua Life Sciences has a price to earnings ratio (PE ratio) of -4.96. This morning RUA shares opened at 11.50p |
Posted at 06/5/2025 08:09 by netcurtains I'm in!I became aware of RUA many many years ago via bones. However recently I have heavily invested in another AIM company: ticker SBTX who have Cavendish as their Nomad. Over the week-end a few OPTI/SBTX investors have been moaning about Cavendish so I decided to investigate Cavendish. During my investigations I noticed Cavendish "tipped" RUA to reach about 50p a share. Looking at the Wall Street Journal site I note that RUA have about £3M in cash, £1M freehold (if I have read that right), and a load of plant and machinery that equates to £1M more than its current share price (eg its NAV is about £8M and its Market cap is about £7M). It seems that RUA are just starting out with a whole new strategy. Its no longer so much about "cutting edge" stuff - its now about medical supplies around the EU... So in a sense, if you or I buy now, we are buying on the ground floor..... New strategies can be really successful - When Triad PLC was just 11p it was an ordinary tech body shop now its a full blown all singing and dancing software house trading in pounds. And also because some knowledgeable people are still in RUA I figured it has to be worth a punt..... I doubt it will reach Cavendish's target in a year (or even two), but as long as the general direction is NORTH from here I feel its a good AIM investment. RUA have cash, assets, a good plan and hardly any debts; what more can you ask from an AIM stock? One more thing, my old driving instructor said the best drivers are ones that have had at least one accident. Clearly RUA have had problems in the past - that should help them to be better directors in the future (it helped the Triad chairman too). Cheers Net! |
Posted at 29/4/2025 14:43 by bones GB904150, thanks for taking the time to lay out the arguments.Coloplast is the major customer of Contract Manufacturing as well. It’s that successful relationship that inspired Coloplast to work with RUA to persuade RUA to take the chance with ABISS. It does also sound like traction is being gained with other “global” players judging by recent RNS announcements. I agree that Vascular and Structural Heart are not dead ends. Those R&D efforts have produced the very textile-based materials infused with Elasteon polymer that have the potential to be a breakthrough technology in devices that require absolute biocompatibility combined with unbreakable tensile strength. How many failures did Turing go through before succeeding in breaking the Enigma code? One thing you can say about RUA is that they’ve had several failed goes at it using Elasteon in isolation but the combined textile/Elasteon discovery (arising through the vascular graft R&D work) looks far more viable in practical terms for implantable devices. None of that was possible before the acquisition of RUA Medical Devices in 2020. The lingering question that so consumes the lives and energies of some posters here is whether our board (essentially Bill Brown and Lachlan Smith) can realise and market the benefits. I agree that their recent cost cutting strategy and focus on the profitable divisions was a necessary direction to go in. On the board and shareholdings, they do now of course have a considerable incentive by way of share options. All told options would convert to nearly 10% of the company; current execs with the majority of that. I prefer to characterise this as a genuine incentive to up the share price rather than any porcine instinct at the feeding station! There are posters here that hold the opposite view. It would be nice to see the company prove them wrong in the near future….. Most of the options are exercisable at 11p so no profit for holders until well north of the current 11.6p price. Quite a lot of Bill Brown’s are also at 30p, so maybe further work required. |
Posted at 29/4/2025 09:32 by gb904150 But isn't it the case that graft and valve still exist but that the route to commercialisation is via a partner rather than on their own?The way I see the business: RUA Biomaterials Elast-eon royalty generates £500-600k revs per year. Helps cover overheads Give us a competitive edge as a material that can be combined with other materials to make a class leading product. Hybrid of textile and polymer. RUA Medical devices The new 'bread and butter' of the business that pays the bills, covers the rest of the overheads and generates a profit. High margins and contract manufacture. Working with multi $bn Mcap companies like Coloplast via the ABISS acquisition RUA vascular grafts and soft tissue patches. But they will not go it alone. It's too big and too risky. A company killer if you overdo it. RUA structural heart Leaflet material - tri leaflet polymeric heart valves But they will not go it alone. It's too big and too risky. A company killer if you overdo it. I'd say that RUA was not a viable investment previously, it was a gamble. Whereas now I'd say it's a viable, profitable business, run more sustainably. With the upside of a major taking an interest at some point. Meanwhile, the valuation is low - about half is cash. And the company is profitable. Then in the background there is the alignment of our YE with that of Coloplast's. Might be significant, might not be. But they do seem to be working closely with and solving problems alongside Coloplast. Suggests closer alignment in future. My main criticism with RUA is that the BOD hold very small stakes. They will naturally end up being more focused on what is good for them and the business rather than what is good for investors. Fortunately that's balanced out by some decent sized fund holdings and HNW's who see the value. |
Posted at 28/4/2025 12:37 by rivaldo Cavendish have this morning issued a new 11 page post trading update research note.They've raised their target price to 50p (from 25p). They conclude: "We believe RUA Life Science is significantly de-risked and offers strong upside for investors." In summary (extracts): "Delivering on strategy RUA Life Sciences has published a trading update for the 12 months to March 2025, demonstrating strong progress on its strategy to deliver near-term profitability by focusing on its revenue-generating divisions. Group revenue is expected to be £4.1m, including £1.3m from the Abiss acquisition. Biomaterials revenue of £0.6m was in line with our forecast, while the underlying Medical Devices & Components (MD&C) division generated revenues of £2.2m, up 32% YoY and ahead of our forecast £1.9m. Cash at the end of March 2025 was £3.7m (FY24A: £3.9m), reflecting reduced cash burn. RUA has identified opportunities and potential for revenue growth from its two revenue-generating divisions, pointing to continued revenue growth, which is conservatively reflected in our updated forecasts. We believe RUA Life Science is significantly de-risked and offers strong upside for investors." "Investment thesis: Recent trading results demonstrate the strong progress RUA is delivering against its new strategy that looks to generate near-term profitability by focusing on the company’s revenue-generating divisions. We believe the progress indicates RUA is a significantly de-risked, revenue-generating business with numerous growth opportunities, pointing to a valuation above the current market value. Further, the largely developed but strategically de-emphasised graft and valve products offer ‘free’ upside opportunities above the value of the core business." |
Posted at 25/4/2025 09:16 by rivaldo IMO the trading update was good and I'm perfectly happy with the progress RUA is now making (having invested relatively recently compared to most here!).RUA is now an EBITDA-profitable company with a £3.7m cash pile against a £7m m/cap. There are a number of ways in which the company can grow, and costs are finally being controlled. The ElastEon opportunity sounds particularly exciting but will be a bonus if it happens. I liked this commentary from IntraVnus elsewhere: "The existing Scottish contract manufacturing business is progressing nicely. They are aiming to add to this with a development of the vascular material for a global player (“…. most excitingly, the Group is actively pursuing an opportunity to combine our textiles expertise with ElastEon to create a novel device for a global device company…” The ABISS business had an initial bulge in back orders to fulfil (already known about) so the rate of sales was always expected to slow after that. Competitors (at least one is a US major MedTech) in their field have pulled out of the European market so ABISS should be well placed to win more European business. Maybe some skittish investors/traders sold because of the temporary destocking reduction in orders but that’s not expected to cause an issue due to the expected increase in market share. ABISS was acquired for virtually nothing. Biomaterials royalties continue to grow steadily. That’s a dollar business so it will jump around depending on US currency moves. Flyinghigher said RUA was a “low margin” business, I guess because of the low ebitda number. That’s not right at all. Contract manufacturing and royalties are both very high margin and are contributing good profits. Separately to those, RUA has always had a R&D cost centre which was its major activity before they bought RUA Medical (contract manufacturing). That obviously impacts overall group income but the R&D department is the reason that RUA has its unique textile/Elasteon material that could play a big part in future business. The bigger CM gets, the quicker profits grow. The statement that they are not looking for finance for the vascular graft is no surprise and has definitely been the assumption for a long time. The material is being developed in other ways now. Far from being a “massive money spinner”, vascular was responsible for almost sinking the group with the bulk of the Dec 20 raise at 120p being sunk into its development. Continuing to fund its trials would have finished RUA off. It was never a money spinner except in theory. Rua wasn’t big enough for it in the same way it was not big enough to fund heart valve development in the old days. As I said on 18th March, the share price does not allow for any success in the heart valve material. Previous sell offs seem to have been because people assumed the hoped for heart valve material deal with a major was off. In reality, it’s being looked at by several companies but for various possible uses including HV. That’s not a dead duck but the share price won’t reflect that in a non-bull market. It will need an actual announcement of some kind of agreement. Day traders here will have to wait longer." |
Posted at 19/3/2025 18:07 by bones The end of March sees the completion of the 12 months period that used to be RUA’s year end but will now be the second interim period for the 18 months to the new accounting date of 30 September.I would hope to see a business update in April as I’m sure there must be plenty to report. From previous updates, I envisage there might be an ABISS trading profit of £500k - £750k for the 7 months of ownership to date. There could also be a one off net asset revaluation of £1.5M - £2M being the difference between net asset fair values and the acquisition cost of the company. I would hope the board will confirm that Abiss continues to look good going forward. The Scottish Contract Manufacturing business should also have made between £500k and £1M profit and that division announced a new long term contract with a global player recently. Biomaterials division should have chipped in its usual £500k in fees and royalties for the year. The question then is what control has been achieved in containing the overheads including R&D? Excluding Abiss, will they be kept under £3M? It was £4M+ in the previous year but only £1.7M in the half year to Sep 24. Whatever, let’s hope they can demonstrate continued cost discipline there. I’m assuming nothing but costs (in the overheads mentioned) for the Vascular and Heart Valve departments. Any news on discussions with third parties will always be welcome but I don’t assume that. These are strictly bonus balls. Overall, with the ABISS one off uplift and hopefully good trading profits there, the headline “group profits” could be impactful. I don’t believe the current share price discounts any of this upside. If they can achieve these numbers and issue a positive trading outlook, that might change. |
Posted at 10/2/2025 07:41 by bones Quick history visit:RUA (then called Aortech) acquired RUA Medical Devices Ltd in April 2020 from David Richmond (still a 1.5M shareholder). Richmond himself acquired this contract manufacturing business from Lombard Medical in 2013. The “post balance sheet events” note in the 2013 accounts of RUA Medical Devices said (and I paraphrase): “ 20/12/13 - RUA Medical Devices purchased the assets and goodwill from Lombard Medical (Scotland) Ltd. These comprised the medical device subcontracts manufacturing division of Lombard Medical Technologies PLC. Following this date, RUA Medical secured a 5 year contract to supply implantable medical devices to Coloplast A/S.” As far as I can see, this is the only time Coloplast’s name was mentioned in published accounts until it got a mention in the Abiss acquisition RNS last September. The RUA Medical income to date has mainly been from a US based customer (which has since renewed its supply contract more than once and currently runs to 2027 I think). The customer must therefore be Coloplast’s US subsidiary. Now that RUA has acquired ABISS, which supplies Coloplast in European markets, you get a picture of that relationship. The latest RNS that referred to a new 5 year deal is however (I think) with a different “global customer” as that “existing business” had only done circa £500k of business with RUA before (one sixth of the size of the new contract). |
Posted at 03/2/2025 10:03 by andyview Short note from Cavendish this morning:“RUA Life Sciences has provided a trading update for its French subsidiary, ABISS, which was acquired in September 2024. Trading was significantly 4Q24 weighted, with the first 9-months, pre-acquisition, being impacted by significant supply chain challenges that were resolved in the final quarter. A pretax loss of c€450k was recorded for the first 9-months while the final quarter delivered a pretax profit of c€500k, which will be consolidated by RUA. FY24 ABISS revenues were €2.3m, up 7% YoY, with RUA expecting further growth to be generated from this business. Following the positive trading update from October 2024, the recent announcement of a new supply agreement and this positive ABISS update, we believe RUA is building strong momentum towards becoming a profitable business and see the shares trading at a discount to this expectation.“ |
Posted at 11/12/2024 13:26 by bones To be fair, there has been a churn of shareholders for months already. Absolutely nothing is baked into the share price about the HV and Vascular upsides so those are already discounted. Enterprise value is below book value right now and no growth potential from medical devices is in the price either. Naturally, when a share price is on the floor (it’s a moribund AIM market after all), people tend to be downcast, pessimistic and critical. Human nature, innit?The adventurous will buy at this level but RUA isn’t very visible to them which is something the company needs to rectify from a promotional viewpoint. |
Posted at 21/11/2024 14:42 by bones Marmie, RUA paid €80,000 for total ownership of ABISS. This was a fire sale by the French liquidator out of ABISS’s old holding company. In the last RNS, RUA estimated, based on book values, that the surplus in value over the €80k that needs to be recognised as a non-cash one off addition to assets of the RUA group is around £900k (in GBP it said). This could be subject to change once they’ve worked out what the fair values of the assets are. They probably need to put some value on the IP too. I think there’s a good chance the adjustment might be higher.Also, it sounds like ABISS is cash positive so they might be building cash having owned it for three months so far. Buying ABISS was mostly at the behest of the big customer, Coloplast, and the RUA group has now decided to realign its own year end to that of Coloplast. I don’t regard that as a coincidence. Coloplast has a vested interest in the products ABISS owns and produces for it. RUA’s other contract manufacturing business seems to be going well also. That is profitable in its own right. RUA’s R&D expenditure has been heavily curtailed to save costs too. The current weakness is probably associated with the messaging on the heart valve. There is no way the share price had been factoring in the heart valve anyway (the CM businesses are worth more than the market cap on their own) but it’s a combination of sentiment and simply being a microcap stock in an ignored AIM marketplace. I’m hoping the interims and commentary due in mid December will fill in the latest developments and be positive on these fronts. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
.png){kind=logo}
